Moments ago, a Form 4 was filed with the SEC reporting that Shawn K. Singh, J.D., Chief Executive Officer of VistaGen Therapeutics, acquired 100,000 shares of the company at $0.50. Mr. Singh now holds 252,174 shares of common stock.

This $50,000 transaction underscores Mr. Singh’s strong confidence in VistaGen’s Human Clinical Trials in a Test Tube™ platform and sound business plan. The CardioSafe 3D™ and LiverSafe 3D™ stem cell-based bioassay systems derived from this platform promise to improve the predictability of the drug development cycle and lower the cost of new drug research and development by identifying product failures earlier in the cost curve.

Mr. Singh has accumulated more than 20 years of experience serving in senior management roles with successful public and private biotechnology and pharmaceutical companies, a biotechnology-focused venture capital firm, and a profitable contract research and development organization. Companies that have thrived under his leadership include Cato BioVentures, Cato Research, Echo Therapeutics (Nasdaq: ECTE), and SciClone Pharmaceuticals (Nasdaq: SCLN).

For more information on VistaGen and its game-changing technology, visit www.VistaGen.com

Let us hear your thoughts below: